---
title: "300361.SZ (300361.SZ) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/300361.SZ/news.md"
symbol: "300361.SZ"
name: "300361.SZ"
parent: "https://longbridge.com/en/quote/300361.SZ.md"
datetime: "2026-05-20T02:40:41.503Z"
locales:
  - [en](https://longbridge.com/en/quote/300361.SZ/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/300361.SZ/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/300361.SZ/news.md)
---

# 300361.SZ (300361.SZ) — Related News

### [Over 1.6 billion yuan License-in, Aosaikang Pharmaceuticals makes a bold bet on "undruggable" targets, how to evaluate its value?](https://longbridge.com/en/news/271439754.md)
*2026-01-05T00:22:26.000Z*
> Aosaikang Pharmaceuticals has reached a License-in agreement worth over 1.6 billion yuan with Arno BioPharma, obtaining 

### [Aosaikang: Subsidiary Aosaikang Pharmaceutical has reached a licensing introduction agreement with Arno Therapeutics](https://longbridge.com/en/news/270984636.md)
*2025-12-29T10:54:40.000Z*
> ASK PHARM announced that its subsidiary, ASK PHARM, has reached a licensing agreement with Arno Therapeutics to obtain e

### [Aosaikang: Injectable Delafloxacin Mesylate has obtained a drug registration certificate](https://longbridge.com/en/news/270484713.md)
*2025-12-22T11:34:03.000Z*
> Aosaikang announced that its wholly-owned subsidiary Jiangsu Aosaikang Pharmaceutical Co., Ltd. has obtained the drug re

### [Aosaikang: Innovative drug Liraglutide tablets included in the national medical insurance catalog](https://longbridge.com/en/news/268872712.md)
*2025-12-08T00:08:05.000Z*
> ASK PHARM announced that its innovative drug Liratinib Tablets (brand name: Aoyi Xin®) has been included in the National

### [ASK PHARM released its performance for the first three quarters, with a net profit attributable to the parent company of 223 million yuan, a year-on-year increase of 75.81%](https://longbridge.com/en/news/263060679.md)
*2025-10-28T10:39:03.000Z*
> According to the Zhitong Finance APP, ASK PHARM released its third-quarter report for 2025. In the first three quarters,

### [Aosaikang: Innovative drug ASKB589 will announce clinical research data at the 2025 ESMO Annual Meeting](https://longbridge.com/en/news/261829441.md)
*2025-10-20T07:51:03.000Z*
> ASK PHARM announced that its subsidiary ASKGENE LIMITED will present clinical research data for the biopharmaceutical AS

### [Aosaikang's subsidiary signs ASKG712 project licensing agreement](https://longbridge.com/en/news/261521340.md)
*2025-10-17T00:15:03.000Z*
> Aosaikang's holding subsidiary AskGene Pharma has signed a licensing agreement with Visara, allowing Visara to use the i

### [](https://longbridge.com/en/news/258971513.md)
*2025-09-26T01:40:52.000Z*
> The innovative drug sector adjusted at the beginning of the trading session, with Aosaikang hitting the limit down, foll